A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244 · see citing works

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969 · see citing works

Virological assessment of hospitalized patients with COVID-2019

Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661 · see citing works

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,278 · see citing works

A serological assay to detect SARS-CoV-2 seroconversion in humans

Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769 · see citing works

Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients

Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614 · see citing works

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569 · see citing works

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

Huang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Trimmer-Smith, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18450-4 · Cited by 1,026 · see citing works

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

(2020) · Nature Communications · doi:10.1101/2020.04.14.20065771 · Cited by 1,019 · see citing works

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1743767 · Cited by 711 · see citing works

An Infectious cDNA Clone of SARS-CoV-2

Xie, X., Muruato, A., Lokugamage, K. G., Narayanan, K., Zhang, X., Zou, J., Liu, J., Schindewolf, C., Bopp, N. E., Aguilar, P. V., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.004 · Cited by 647 · see citing works

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

GeurtsvanKessel, C. H., Okba, N. M. A., Igloi, Z., Bogers, S., Embregts, C. W. E., Laksono, B. M., Leijten, L., Rokx, C., Rijnders, B., Rahamat-Langendoen, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17317-y · Cited by 361 · see citing works

Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020

Perera, R. A. P. M., Mok, C. K. P., Tsang, O. T., Lv, H., Ko, R. L., Wu, N. C., Yuan, M., Leung, W.-S., Chan, J. M., Chik, T. S., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.16.2000421 · Cited by 322 · see citing works

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Xie, X., Muruato, A. E., Zhang, X., Lokugamage, K. G., Fontes-Garfias, C. R., Zou, J., Liu, J., Ren, P., Balakrishnan, M., Cihlář, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19055-7 · Cited by 216 · see citing works

Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen MicroarrayPreprint

Khan, S., Nakajima, R., Jain, A., de Assis, R. R., Jasinskas, A., Obiero, J. M., Adenaiye, O., Tai, S., Hong, F. H., Milton, D. K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.24.006544 · Cited by 118 · see citing works

Convalescent plasma therapy for the treatment of patients with COVID‐19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels

Harvala, H., Robb, M. L., Watkins, N. A., Ijaz, S., Dicks, S., Patel, M., Supasa, P., Dejnirattisai, W., Liu, C., Mongkolsapaya, J., et al. (2020) · Transfusion Medicine · doi:10.1111/tme.12746 · Cited by 86 · see citing works

A Rapid Zika Diagnostic Assay to Measure Neutralizing Antibodies in Patients

Shan, C., Xie, X., Ren, P., Loeffelholz, M. J., Yang, Y., Furuya, A. K. M., Dupuis, A. P., Kramer, L. D., Wong, S. J., & Shi, P. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.03.006 · Cited by 64 · see citing works

Towards the next phase: evaluation of serological assays for diagnostics and exposure assessmentPreprint

GeurtsvanKessel, C. H., Okba, N. M. A., Igloi, Z., et al. (2020) · medRxiv · doi:10.1101/2020.04.23.20077156 · Cited by 55 · see citing works

Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levelsPreprint

Harvala, H., Robb, M. L., Watkins, N. A., et al. (2020) · medRxiv · doi:10.1101/2020.05.20.20091694 · Cited by 43 · see citing works

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19Preprint

Xie, X., Muruato, A. E., Zhang, X., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.22.165712 · Cited by 41 · see citing works

Evaluation of a Novel Reporter Virus Neutralization Test for Serological Diagnosis of Zika and Dengue Virus Infection

Shan, C., Ortiz, D. A., Yang, Y., Wong, S. J., Kramer, L. D., Shi, P., Loeffelholz, M. J., & Ren, P. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00975-17 · Cited by 36 · see citing works

Evolution of the SARS-CoV-2 proteome in three dimensions (3D) during the first six months of the COVID-19 pandemicPreprint

Lubin, J. H., Zardecki, C., Dolan, E. M., Lu, C., Shen, Z., Dutta, S., Westbrook, J., Hudson, B. P., Goodsell, D. S., Williams, J. K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.01.406637 · Cited by 26 · see citing works

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · see citing works

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977 · see citing works

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569 · see citing works

Spike mutation D614G alters SARS-CoV-2 fitness

Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558 · see citing works

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 845 · see citing works

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis

Johnson, B. A., Xie, X., Bailey, A. L., Kalveram, B., Lokugamage, K. G., Muruato, A., Zou, J., Zhang, X., Juelich, T., Smith, J. K., et al. (2021) · Nature · doi:10.1038/s41586-021-03237-4 · Cited by 694 · see citing works

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03275-y · Cited by 694 · see citing works

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01270-4 · Cited by 628 · see citing works

Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster

Kurhade, C., Zou, J., Xia, H., Liu, M., Chang, H. C., Ren, P., Xie, X., & Shi, P. (2022) · Nature Medicine · doi:10.1038/s41591-022-02162-x · Cited by 424 · see citing works

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Liu, J., Liu, Y., Xia, H., Zou, J., Weaver, S. C., Swanson, K. A., Cai, H., Cutler, M., Cooper, D., Muik, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03693-y · Cited by 342 · see citing works

SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies

Cox, M., Peacock, T. P., Harvey, W. T., Hughes, J., Wright, D. W., Willett, B. J., Thomson, E. C., Gupta, R. K., Peacock, S. J., Robertson, D. L., et al. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00809-7 · Cited by 336 · see citing works

Detection of antibodies against SARS-CoV-2 spike protein by gold nanospikes in an opto-microfluidic chip

Funari, R., Chu, K.-Y., & Shen, A. Q. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112578 · Cited by 279 · see citing works

Ultrafast, sensitive, and portable detection of COVID-19 IgG using flexible organic electrochemical transistors

Liu, H., Yang, A., Song, J., Wang, N., Lam, P., Li, Y., Law, H., & Yan, F. (2021) · Science Advances · doi:10.1126/sciadv.abg8387 · Cited by 235 · see citing works

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Xie, X., Muruato, A. E., Zhang, X., Lokugamage, K. G., Fontes-Garfias, C. R., Zou, J., Liu, J., Ren, P., Balakrishnan, M., Cihlář, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19055-7 · Cited by 216 · see citing works

Accelerating antiviral drug discovery: lessons from COVID-19

von Delft, A., Hall, M. D., Kwong, A. D., Purcell, L. A., Saikatendu, K. S., Schmitz, U., Tallarico, J. A., & Lee, A. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00692-8 · Cited by 223 · see citing works

Furin Cleavage Site Is Key to SARS-CoV-2 PathogenesisPreprint

Johnson, B. A., Xie, X., Kalveram, B., Lokugamage, K. G., Muruato, A. E., Zou, J., Zhang, X., Juelich, T. L., Smith, J. K., Zhang, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.26.268854 · Cited by 186 · see citing works

Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies

Bian, L., Gao, F., Zhang, J., He, Q., Mao, Q., Xu, M., & Liang, Z. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1903879 · Cited by 181 · see citing works

Engineering SARS-CoV-2 using a reverse genetic system

Xie, X.-P., Lokugamage, K. G., Zhang, X.-W., Vu, M., Muruato, A. E., Menachery, V., & Shi, P.-Y. (2021) · Nature Protocols · doi:10.1038/s41596-021-00491-8 · Cited by 173 · see citing works

Defining the risk of SARS-CoV-2 variants on immune protection

DeGrace, M. M., Ghedin, E., Frieman, M. B., Krammer, F., Grifoni, A., Alisoltani, A., Alter, G., Amara, R. R., Baric, R. S., Barouch, D. H., et al. (2022) · Nature · doi:10.1038/s41586-022-04690-5 · Cited by 167 · see citing works

A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses

Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.001 · Cited by 187 · see citing works

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine

Zou, J., Kurhade, C., Patel, S., Kitchin, N. R. E., Tompkins, K. R., Cutler, M. W., Cooper, D., Yang, Q., Cai, H., Muik, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2214916 · Cited by 166 · see citing works

Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls

Simon, B., Rubey, H., Treipl, A., Gromann, M., Hemedi, B., Zehetmayer, S., & Kirsch, B. M. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab179 · Cited by 151 · see citing works

Development of a rapid Focus Reduction Neutralization Test Assay for measuring SARS-CoV-2 neutralizing antibodies

Vanderheiden, A., Edara, V., Floyd, K., Kauffman, R. C., Mantus, G., Anderson, E., Rouphael, N., Edupuganti, S., Shi, P.-Y., Menachery, V., et al. (2020) · Current Protocols in Immunology · doi:10.1002/cpim.116 · Cited by 141 · see citing works

Artificial intelligence-assisted colorimetric lateral flow immunoassay for sensitive and quantitative detection of COVID-19 neutralizing antibody

Tong, H., Cao, C., You, M., Han, S., Liu, Z., Xiao, Y., He, W., Liu, C., Peng, P., Xue, Z., et al. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114449 · Cited by 148 · see citing works

A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates

Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2020) · doi:10.1101/2020.09.08.280818 · Cited by 126 · see citing works

Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)

Meyer, B., Reimerink, J. H. J., Torriani, G., Brouwer, F., Godeke, G.-J., Yerly, S., Hoogerwerf, M. N., Vuilleumier, N., Kaiser, L., Eckerle, I., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1835448 · Cited by 130 · see citing works

Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation

Higgins, V., Fabros, A., & Kulasingam, V. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.03149-20 · Cited by 128 · see citing works

Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models

Hajnik, R. L., Plante, J. A., Liang, Y., Alameh, M.-G., Tang, J., Bonam, S. R., Zhong, C., Adam, A., Scharton, D., Rafael, G. H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq1945 · Cited by 122 · see citing works

Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection

Zou, J., Xia, H., Xie, X., Kurhade, C., Machado, R. R. G., Weaver, S. C., Ren, P., & Shi, P. (2022) · Nature Communications · doi:10.1038/s41467-022-28544-w · Cited by 122 · see citing works

Ultrasensitive Detection of SARS-CoV-2 Antibody by Graphene Field-Effect Transistors

Hua, K., Wang, X., Guo, M., Dai, C., Chen, R., Yang, L., Wu, Y., Ying, T., Zhu, Z., Wei, D., et al. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00837 · Cited by 120 · see citing works

A comparative review of immunoassays for COVID-19 detection

Mohit, E., Rostami, Z., & Vahidi, H. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1908886 · Cited by 116 · see citing works

Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays

Tang, M. S., Case, J. B., Franks, C. E., Chen, R. E., Anderson, N. W., Henderson, J. P., Diamond, M., Gronowski, A. M., & Farnsworth, C. W. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa211 · Cited by 113 · see citing works

A serological aptamer-assisted proximity ligation assay for COVID-19 diagnosis and seeking neutralizing aptamers

Liu, R., He, L., Hu, Y., Luo, Z., & Zhang, J. (2020) · Chemical Science · doi:10.1039/d0sc03920a · Cited by 109 · see citing works

The COVID-19 pandemic: viral variants and vaccine efficacy

Ciotti, M., Ciccozzi, M., Pieri, M., & Bernardini, S. (2021) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2021.1979462 · Cited by 108 · see citing works

Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

Tauzin, A., Gong, S. Y., Beaudoin-Bussières, G., Vézina, D., Gasser, R., Nault, L., Marchitto, L., Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.004 · Cited by 103 · see citing works

Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors

Zeng, C., Evans, J. P., Pearson, R., Qu, P., Zheng, Y.-M., Robinson, R., Hall‐Stoodley, L., Yount, J. S., Pannu, S. R., Mallampalli, R. K., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.143213 · Cited by 87 · see citing works

Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies

Alenquer, M., Ferreira, F., Lousa, D., Valério, M., Medina-Lopes, M., Bergman, M., Gonçalves, J., Demengeot, J., Leite, R. B., Lilue, J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009772 · Cited by 99 · see citing works

Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays

Sholukh, A. M., Fiore-Gartland, A. J., Ford, E. S., Miner, M. D., Hou, Y. J., Tse, L. V., Kaiser, H., Zhu, H., Lu, J., Madarampalli, B., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00527-21 · Cited by 119 · see citing works

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2

Xia, H., Zou, J., Kurhade, C., Cai, H., Yang, Q., Cutler, M. W., Cooper, D., Muik, A., Jansen, K. U., Xie, X., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.02.015 · Cited by 102 · see citing works

Quantitation of antibodies against SARS‐CoV‐2 spike protein after two doses of CoronaVac in healthcare workers

Bayram, A., Demirbakan, H., Karadeniz, P. G., Erdoğan, M., & Koçer, İ. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27098 · Cited by 95 · see citing works

A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models

Maruggi, G., Mallett, C. P., Westerbeck, J. W., Chen, T., Lofano, G., Friedrich, K., Qu, L., Sun, J., McAuliffe, J., Kanitkar, A. P., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.001 · Cited by 88 · see citing works

Silymarin/curcumin loaded albumin nanoparticles coated by chitosan as muco-inhalable delivery system observing anti-inflammatory and anti COVID-19 characterizations in oleic acid triggered lung injury and in vitro COVID-19 experiment

Hanafy, N. A. N., & El-Kemary, M. A. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.12.073 · Cited by 87 · see citing works

A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions

Liu, Y., Zhang, X., Liu, J., Xia, H., Zou, J., Muruato, A. E., Periasamy, S., Kurhade, C., Plante, J. A., Bopp, N. E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31930-z · Cited by 87 · see citing works

Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge

Muruato, A. E., Vu, M. N., Johnson, B. A., Davis-Gardner, M. E., Vanderheiden, A., Lokugamage, K. G., Schindewolf, C., Crocquet-Valdes, P. A., Langsjoen, R. M., Plante, J. A., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001284 · Cited by 82 · see citing works

Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera

Oguntuyo, K., Stevens, C., Hung, C.-T., Ikegame, S., Acklin, J. A., Kowdle, S., Carmichael, J. C., Chiu, H.-P., Azarm, K. D., Haas, G. D., et al. (2021) · mBio · doi:10.1128/mbio.02492-20 · Cited by 12 · see citing works

A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence

Zhang, X., Liu, Y., Liu, J., Bailey, A. L., Plante, K. S., Plante, J. A., Zou, J., Xia, H., Bopp, N. E., Aguilar, P. V., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.044 · Cited by 80 · see citing works

The Main Molecular and Serological Methods for Diagnosing COVID-19: An Overview Based on the Literature

Machado, B. A. S., Hodel, K. V. S., Júnior, V. G. B., Soares, M. B. P., & Badaró, R. J. D. S. (2020) · Viruses · doi:10.3390/v13010040 · Cited by 77 · see citing works

Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination

Altawalah, H. (2021) · Vaccines · doi:10.3390/vaccines9080910 · Cited by 71 · see citing works

Plasmonic Metasurfaces for Medical Diagnosis Applications: A Review

Wang, Z., Chen, J., Khan, S. A., Li, F., Shen, J., Duan, Q., Liu, X., & Zhu, J. (2021) · Sensors · doi:10.3390/s22010133 · Cited by 72 · see citing works

Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion

Xue, S., Han, Y., Wu, F., & Wang, Q. (2024) · Protein & Cell · doi:10.1093/procel/pwae007 · Cited by 72 · see citing works

SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus

Matusali, G., Colavita, F., Lapa, D., Meschi, S., Bordi, L., Piselli, P., Gagliardini, R., Corpolongo, A., Nicastri, E., Antinori, A., et al. (2021) · Viruses · doi:10.3390/v13040655 · Cited by 68 · see citing works

Recent Advances in Aggregation‐Induced Emission Materials and Their Biomedical and Healthcare Applications

He, W., Zhang, T., Bai, H., Kwok, R. T. K., Lam, J. W. Y., & Tang, B. Z. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101055 · Cited by 66 · see citing works

Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre‐pandemic controls

Jung, K., Shin, S., Nam, M., Hong, Y. J., Roh, E. Y., Park, K. U., & Song, E. Y. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23921 · Cited by 64 · see citing works

SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response

Gundlapalli, A. V., Salerno, R. M., Brooks, J. T., Averhoff, F. M., Petersen, L. R., McDonald, L. C., Iademarco, M. F., Response, C. C.-1., Carroll, Y. I., Gorwitz, R. J., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa555 · Cited by 62 · see citing works

Gold-silver alloy hollow nanoshells-based lateral flow immunoassay for colorimetric, photothermal, and SERS tri-mode detection of SARS-CoV-2 neutralizing antibody

Zhao, T., Liang, P., Ren, J., Zhu, J., Yang, X., Bian, H., Li, J., Cui, X., Fu, C., Xing, J., et al. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.341102 · Cited by 62 · see citing works

Antigenic characterization of influenza and SARS-CoV-2 viruses

Wang, Y., Tang, C. Y., & Wan, X. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03806-6 · Cited by 60 · see citing works

Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies

Kohmer, N., Rühl, C., Ciesek, S., & Rabenau, H. F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102128 · Cited by 59 · see citing works

Advances in Neutralization Assays for SARS‐CoV‐2

Lu, Y., Jin, W., Li, Q., Hu, H., Lu, J., & Chen, Z. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13088 · Cited by 57 · see citing works

Widespread exposure to SARS-CoV-2 in wildlife communities

Goldberg, A. R., Langwig, K. E., Brown, K. L., Marano, J. M., Rai, P., King, K. M., Sharp, A. K., Ceci, A., Kailing, C. D., Kailing, M. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49891-w · Cited by 58 · see citing works

Viral infection neutralization tests: A focus on severe acute respiratory syndrome‐coronavirus‐2 with implications for convalescent plasma therapy

Focosi, D., Maggi, F., Mazzetti, P., & Pistello, M. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2170 · Cited by 57 · see citing works

Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody

Liu, K., Han, Y.-J., Wu, G.-H., Huang, K.-Y. A., & Huang, P.-N. (2022) · Viruses · doi:10.3390/v14071560 · Cited by 54 · see citing works

Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1

Hu, Y., Zou, J., Kurhade, C., Deng, X., Chang, H. C., Kim, D. K., Shi, P., Ren, P., & Xie, X. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2271089 · Cited by 54 · see citing works

Novel coronavirus disease (COVID-19) pandemic: A recent mini review

Rehman, M. F. U., Fariha, C., Anwar, A., Shahzad, N., Ahmad, M., Mukhtar, S., & Haque, M. F. U. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.12.033 · Cited by 51 · see citing works

NeutrobodyPlex—monitoring SARS-CoV-2 neutralizing immune responses using nanobodies

Wagner, T. R., Kaiser, P. D., Gramlich, M., Ostertag, E., Ruétalo, N., Junker, D., Häring, J., Traenkle, B., Becker, M., Dulovic, A., et al. (2021) · EMBO Reports · doi:10.15252/embr.202052325 · Cited by 49 · see citing works

COVID-19: clinical presentation and detection methods

Pradhan, M., Shah, K., Alexander, A., Ajazuddin, M., Minz, S., Singh, M. R., Singh, D., Yadav, D. K., & Chauhan, N. S. (2021) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2021.1951291 · Cited by 51 · see citing works

Rapid lateral flow tests for the detection of SARS-CoV-2 neutralizing antibodies

Wang, J. J., Zhang, N., Richardson, S. A., & Wu, J. V. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1913123 · Cited by 49 · see citing works

Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2

Tioni, M. F., Jordan, R., Pena, A. S., Garg, A., Wu, D., Phan, S. I., Weiss, C. M., Cheng, X., Greenhouse, J. J., Orekov, T., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00509-6 · Cited by 45 · see citing works

A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds

Schöler, L., Le‐Trilling, V. T. K., Eilbrecht, M., Mennerich, D., Anastasiou, O. E., Krawczyk, A., Herrmann, A., Dittmer, U., & Trilling, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573526 · Cited by 42 · see citing works

COVID-19: molecular and serological detection methods

Dhamad, A. E., & Rhida, M. A. A. (2020) · PeerJ · doi:10.7717/peerj.10180 · Cited by 44 · see citing works

Clinical microbiology in detection and identification of emerging microbial pathogens: past, present and future

Wang, H., Zhang, W., & Tang, Y. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2125345 · Cited by 47 · see citing works

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization

Zou, J., Xie, X., Fontes-Garfias, C. R., Swanson, K. A., Kanevsky, I., Tompkins, K. R., Cutler, M. W., Cooper, D., Dormitzer, P. R., & Shi, P. (2021) · npj Vaccines · doi:10.1038/s41541-021-00313-8 · Cited by 42 · see citing works

Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2

Xia, H., & Shi, P. (2020) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2020.0214 · Cited by 43 · see citing works

Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibilityPreprint

Shi, P., Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., et al. (2020) · bioRxiv · doi:10.21203/rs.3.rs-70482/v1 · Cited by 42 · see citing works

A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responsesPreprint

Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.18.435972 · Cited by 41 · see citing works

Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit

Hall, M. D., Anderson, J. M., Anderson, A. S., Baker, D. A., Bradner, J. E., Brimacombe, K. R., Campbell, E. A., Corbett, K. S., Carter, K. L., Cherry, S. R., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab305 · Cited by 40 · see citing works

Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay

López, E., Haycroft, E. R., Adair, A., Mordant, F. L., O’Neill, M. T., Pymm, P., Redmond, S. J., Lee, W. S., Gherardin, N. A., Wheatley, A. K., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150012 · Cited by 38 · see citing works

Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?

Misra, A., & Theel, E. S. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.00482-21 · Cited by 40 · see citing works

Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 VaccinePreprint

Zou, J., Kurhade, C., Patel, S., Kitchin, N. R. E., Tompkins, K. R., Cutler, M. W., Cooper, D., Yang, Q., Cai, H., Muik, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.17.516898 · Cited by 40 · see citing works

Potential medicinal plants to combat viral infections: A way forward to environmental biotechnology

Sharma, R., Bhattu, M., Tripathi, A., Verma, M., Acevedo, R., Kumar, P., Rajput, V. D., & Singh, J. (2023) · Environmental Research · doi:10.1016/j.envres.2023.115725 · Cited by 39 · see citing works

Novel nanostructure-coupled biosensor platform for one-step high-throughput quantification of serum neutralizing antibody after COVID-19 vaccination

Huang, L., Li, Y., Luo, C., Chen, Y., Touil, N., Annaz, H. E., Zeng, S., Dang, T., Liang, J., Hu, W., et al. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113868 · Cited by 36 · see citing works

SARS-CoV-2 Tests: Bridging the Gap between Laboratory Sensors and Clinical Applications

Toropov, N. A., Osborne, E. L., Joshi, L. T., Davidson, J., Morgan, C., Page, J. W., Pepperell, J., & Vollmer, F. (2021) · ACS Sensors · doi:10.1021/acssensors.1c00612 · Cited by 35 · see citing works

Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay

Papenburg, J., Cheng, M. P., Corsini, R., Caya, C., Mendoza, E. J., Manguiat, K., Lindsay, L. R., Wood, H., DREBOT, M. A., Dibernardo, A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab220 · Cited by 35 · see citing works

Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects

Zhang, J., Xing, S., Liang, D., Hu, W. G., Ke, C., He, J., Yuan, R., Huang, Y., Li, Y., Liu, D., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.791660 · Cited by 34 · see citing works

Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles

Miyakawa, K., Jeremiah, S. S., Ohtake, N., Matsunaga, S., Yamaoka, Y., Nishi, M., Morita, T., Saji, R., Nishii, M., Kimura, H., et al. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa047 · Cited by 34 · see citing works

Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2

Müller, K., Girl, P., von Buttlar, H., Dobler, G., & Wölfel, R. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114122 · Cited by 33 · see citing works

A SARS‐CoV‐2 Neutralization Assay Using Single Molecule Arrays

Gilboa, T., Cohen, L., Cheng, C., Lazarovits, R., Uwamanzu‐Nna, A., Han, I., Griswold, K., Barry, N., Thompson, D. B., Kohman, R. E., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202110702 · Cited by 33 · see citing works

Immune response against SARS-CoV-2 variants: the role of neutralization assays

Chmielewska, A., Czarnota, A., Bieńkowska-Szewczyk, K., & Grzyb, K. (2021) · npj Vaccines · doi:10.1038/s41541-021-00404-6 · Cited by 33 · see citing works

Potential of Microneedle Systems for COVID-19 Vaccination: Current Trends and Challenges

Hassan, J., Haigh, C., Ahmed, T., Uddin, M. J., & Das, D. B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051066 · Cited by 34 · see citing works

Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19

Issa, H., Eid, A. H., Berry, B., Takhviji, V., Khosravi, A., Mantash, S., Nehme, R., Hallal, R., Karaki, H., Dhayni, K., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.620990 · Cited by 30 · see citing works

Rapid, label-free, and sensitive point-of-care testing of anti-SARS-CoV-2 IgM/IgG using all-fiber Fresnel reflection microfluidic biosensor

Xu, W., Liu, J., Song, D., Li, C., Zhu, A., & Long, F. (2021) · Microchimica Acta · doi:10.1007/s00604-021-04911-0 · Cited by 32 · see citing works

The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe

Bonanni, P., Cantón, R., Gill, D., Halfon, P., Liebert, U. G., Crespo, K. A. N., Martín, J. J. P., & Trombetta, C. M. (2021) · COVID · doi:10.3390/covid1010004 · Cited by 34 · see citing works

Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults

Wagner, A., Guzek, A., Ruff, J., Jasińska, J., Scheikl, U., Zwazl, I., Kundi, M., Stockinger, H., Farcet, M. R., Kreil, T., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00012-4 · Cited by 24 · see citing works

Identifying optimal capsid duplication length for the stability of reporter flaviviruses

Baker, C. K., Liu, Y., Zou, J., Muruato, A. E., Xie, X., & Shi, P. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1829994 · Cited by 30 · see citing works

Ultrasensitive, high-throughput, and rapid simultaneous detection of SARS-CoV-2 antigens and IgG/IgM antibodies within 10 min through an immunoassay biochip

Wang, C., Wang, C., Qiu, J., Gao, J., Liu, H., Zhang, Y., & Han, L. G. (2021) · Microchimica Acta · doi:10.1007/s00604-021-04896-w · Cited by 30 · see citing works

Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis

Peng, H. T., Rhind, S. G., & Beckett, A. (2021) · JMIR Public Health and Surveillance · doi:10.2196/25500 · Cited by 28 · see citing works

Homogeneous surrogate virus neutralization assay to rapidly assess neutralization activity of anti-SARS-CoV-2 antibodies

Kim, S. J., Yao, Z., Marsh, M., Eckert, D. M., Kay, M. S., Lyakisheva, A., Pasic, M. D., Bansal, A., Birnboim, C., Jha, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31300-9 · Cited by 27 · see citing works

Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural infection and vaccine trialsPreprint

Sholukh, A. M., Fiore-Gartland, A., Ford, E. S., Hou, Y., Tse, L.-P. V., Lempp, F., Kaiser, H., Germain, R. S., Bossard, E. L., Jia, J.-K., et al. (2020) · medRxiv · doi:10.1101/2020.12.07.20245431 · Cited by 25 · see citing works

SARS‐CoV‐2 neutralization and serology testing of COVID‐19 convalescent plasma from donors with nonsevere disease

Gniadek, T. J., Thiede, J. M., Matchett, W. E., Gress, A. R., Pape, K. A., Fiege, J. K., Jenkins, M. K., Menachery, V. D., Langlois, R. A., & Bold, T. D. (2020) · Transfusion · doi:10.1111/trf.16101 · Cited by 27 · see citing works

Nanoplasmonic multiplex biosensing for COVID-19 vaccines

Funari, R., Fukuyama, H., & Shen, A. Q. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114193 · Cited by 27 · see citing works

SARS-CoV-2 serology testing: Progress and challenges

Shi, A. C., & Ren, P. (2021) · Journal of Immunological Methods · doi:10.1016/j.jim.2021.113060 · Cited by 27 · see citing works

Scalable, Micro-Neutralization Assay for Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples

Bennett, R. S., Postnikova, E. N., Liang, J. Y., Gross, R., Mazur, S., Dixit, S., Lukin, V. V., Kocher, G., Yu, S., Georgia, S., et al. (2021) · Viruses · doi:10.3390/v13050893 · Cited by 29 · see citing works

Development of a SARS-CoV-2 monoclonal antibody panel and its applicability as a reagent in high-throughput fluorescence reduction neutralization and immunohistochemistry assaysPreprint

Coelho, G. M., Cataneo, A. H. D., Raboni, S. M., Nogueira, M. B., de Paula, C. B. V., Almeida, A. C., Rogerio, V. Z., Zanchin, N. I. T., de Noronha, L., Zanluca, C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.29.542720

A flow cytometry‐based assay to measure neutralizing antibodies against SARS‐CoV ‐2 virus

Pscheidt, V. M., de Souza, P. O., Fazolo, T., Proença‐Módena, J. L., Simeoni, C. L., de Toledo-Teixeira, D. A., Brunetti, N. S., Bispo-dos-Santos, K., Júnior, L. R., & Bonorino, C. (2024) · Cytometry Part A · doi:10.1002/cyto.a.24838 · Cited by 1 · see citing works

Development of an anti‐SARS‐CoV‐2 monoclonal antibody panel and its applicability as a reagent in high‐throughput fluorescence reduction neutralization and immunohistochemistry assays

Coelho, G. M., Cataneo, A. H. D., Raboni, S. M., Nogueira, M. B., de Paula, C. B. V., Almeida, A. C., Rogerio, V. Z., Zanchin, N. I. T., de Noronha, L., Zanluca, C., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29111 · Cited by 3 · see citing works

A Novel Adaptive Platform for Rapid, Simple Flow-Based Antibody Detection Devices Predicts NAb Levels to SARS-CoV-2

Markmann, A., Bhowmik, D. R., Jiang, B., Vanna, U. P., Hoy, M. V., Wang, F., Hou, Y., Margolis, D., Baric, R. S., de Silva, A., et al. (2026) · Pathogens and Immunity · doi:10.20411/pai.v11i1.910